NYSE:EVR - New York Stock Exchange, Inc. - US29977A1051 - Common Stock - Currency: USD
EVR's first-quarter 2025 results benefit from strong advisory revenues and higher AUM. However, increased expenses weigh on the performance to some extent.
The headline numbers for Evercore (EVR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moelis (MC) delivered earnings and revenue surprises of 12.28% and 5.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MC
TD Securities secured the leading position in terms of deal value, advising on transactions worth $10.4bn.
It’s possible to get a startup business loan if you research lenders and know how much funding you need.
Robinhood Markets (HOOD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: HOOD
Yale University’s endowment is exploring sales of private equity fund stakes as Ivy League schools stare down budget challenges stemming from lackluster investment performance and pressure from President Donald Trump.
Charles Schwab (SCHW) delivered earnings and revenue surprises of 4% and 1.48%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SCHW
Evercore (EVR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sitetracker Inc. is exploring a sale that could value the software platform for managing infrastructure assets at about $1 billion, according to people familiar with the matter.
VillageMD, the health care clinic chain backed by Walgreens Boots Alliance Inc., is working with Evercore Inc. for assistance as explores options that include a sale or restructuring of its operations, according to people with knowledge of the matter.
Mentions: WBA
Estée Lauder Cos is reviewing its portfolio of beauty brands, people with knowledge of the matter said, as the cosmetics company transitions to new leadership and looks to boost its share price.
Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and enable a crucial asset sale.